Alli,
I'm surprised. Could this help:
http://www.england.nhs.uk/ourwork/pe/cdf/cdf-drug-sum/
and within this page:
http://www.england.nhs.uk/wp-content/uploads/2014/08/ncdf-summ-abiraterone.pdf
which says:
In view of the absence of or weakness of the current evidence, the CDF panel concluded that neither the use of abiraterone after chemotherapy and enzalutamide nor the use of abiraterone after enzalutamide pre-chemotherapy should be approved for CDF use. The exception would be in patients in whom enzalutamide has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression.
and
http://www.england.nhs.uk/wp-content/uploads/2014/08/ncdf-summ-enzalutamide-abir.pdf
which says:
In view of the absence of or weakness of the current evidence, the CDF panel concluded that neither the use of enzalutamide after chemotherapy and abiraterone nor the use of enzalutamide after abiraterone pre-chemotherapy should be approved for CDF use. The exception would be in patients in whom abiraterone has had to be stopped within 3 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression.